<SEC-DOCUMENT>0001062993-15-000484.txt : 20150204
<SEC-HEADER>0001062993-15-000484.hdr.sgml : 20150204
<ACCEPTANCE-DATETIME>20150204150734
ACCESSION NUMBER:		0001062993-15-000484
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150204
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150204
DATE AS OF CHANGE:		20150204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXARIA CORP.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		15575034

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 604 - 700 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1G8
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 604 - 700 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 1G8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>


<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR><B>Washington, D.C.
20549 </B><BR></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report <BR>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 <BR></P>
<P align=center>Date of Report (date of earliest event reported): February 4,
2015 </P>
<P align=center><B><FONT size=6><FONT size=5>LEXARIA CORP.
</FONT></FONT></B><BR>(Exact name of registrant as specified in its charter)
<BR></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B>Nevada </B></TD>
    <TD align=center width="33%"><B>000-52138 </B></TD>
    <TD align=center width="33%"><B>20-2000871 </B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer Identification No.) </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
    <TD align=center width="33%">&nbsp; </TD></TR></TABLE>
<P align=center>#950 &#150; 1130 West Pender Street, Vancouver, British Columbia,
Canada V6E 4A4 </P>
<P align=center>Registrant's telephone number, including area code: (604)
602-1675 </P>
<P align=center>(Former name or former address, if changed since last report.)
</P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">[&nbsp;&nbsp; ] </TD>
    <TD>
      <P align=justify>Written communications pursuant to Rule 425 under the
      Securities Act (17 CFR 230.425)</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">[&nbsp;&nbsp; ] </TD>
    <TD>
      <P align=justify>Soliciting material pursuant to Rule 14a-12 under the
      Exchange Act (17 CFR 240.14a-12)</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">[&nbsp;&nbsp; ] </TD>
    <TD>
      <P align=justify>Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act (17 CFR 240.14d- 2(b))</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">[&nbsp;&nbsp; ] </TD>
    <TD>
      <P align=justify>Pre-commencement communications pursuant to Rule 13e-4(c)
      under Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 7.01 Regulation FD Disclosure. </B></P>
<P align=justify>A copy of the news release announcing Lexaria announces
operational update, filed as exhibit 99.1 to this current report and is hereby
incorporated by reference. </P>
<P align=justify><B>TEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center ><B>Exhibit No.</B> </TD>
    <TD align=left width="90%">
    <p style="margin-left: 5"><B>Description</B> </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=left width="90%" >
    <p style="margin-left: 5">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a> </TD>
    <TD align=left width="90%" bgColor=#eeeeee>
    <p style="margin-left: 5"><a href="exhibit99-1.htm">News Release dated February 4,
      2015 </a> </TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify>Dated: February 4, 2015 </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="85%">Lexaria Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left >(Signature) </TD>
    <TD align=left
      width="85%"><U>By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      &#147;<I>/s/ Chris
      Bunka&#148;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </I></U></TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="85%">Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="85%">President &amp; CEO </TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>

<HTML>
<HEAD>
   <TITLE>Lexaria Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=3>Lexaria Updates Operations </FONT></B></P>
<P align=justify>Kelowna, BC / February 4, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the &#147;Company&#148;) provides the following three operational updates. </P>
<P align=justify>CREDIT CARDS. </P>
<P align=justify>Lexaria is pleased to announce it is now accepting Mastercard
and Visa credit card payments at its <U><FONT color=#0000ff>www.vipova.com
</FONT></U>e-commerce site for sales of its patent-pending CBD-infused black tea
across America. Previously, customers could only transact with the ViPova
website with checks and money orders, and while these payment options remain for
those who prefer them, Vipova&#146;s ability to accept major credit cards will
shorten delivery times and provide the ease of ordering that customers
expect.</P>
<P align=justify>Given the increase in web traffic Vipova.com has experienced,
Lexaria believes the ability to use credit cards should lead to an increase in
sales volumes. Customers across the US can also call 1-888-976-8482 from 9AM to
7PM EST Mon-Fri to place their orders. </P>
<P align=justify>FOCUS GROUPS. </P>
<P align=justify>Lexaria has begun holding focus group sessions to introduce and
evaluate its CBD-infused black tea. Our first focus group was held January 29
when 14 people were introduced to ViPova Tea. The session provided a chance for
potential consumers to learn about the tea and the properties of cannabidiol
infusion, and proved immensely valuable to the Company to learn about consumer
preferences, needs, likes and dislikes.</P>
<P align=justify>Lexaria is very pleased at the enthusiastic response and
comments received. Participants had the opportunity to meet senior
representatives of ViPova, and provide detailed commentary that the Company will
use to fine-tune its products and marketing as 2015 unfolds. </P>
<P align=justify>The next focus group will be held during the next several days
and the Company expects to continue to hold similar focus group meetings in the
weeks and months to come. </P>
<P align=justify>STRATEGIC ADVISOR. </P>
<P align=justify>Lexaria has engaged Sequoia Partners Inc for strategic fiscal
advisement and for the development of various strategies to assist the Company
to realize its project objectives. Lexaria will be working closely with the
Managing Partners of Sequoia to pursue its interests. The Managing Partners have
extensive and long lasting relationships in the finance, health care and
pharmaceutical industries that are expected to be beneficial to the Company.
</P>
<P align=justify>Sequoia has been granted 250,000 stock options and will receive
a monthly fee of CDN$5,000 for the next six months. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>


<!--$$/page=-->
<A name="page_2"></A>

<P align="justify">
About Lexaria </P>
<P align="justify">
Lexaria's shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. www.lexarienergy.com </P>
<P align="justify">
About ViPova<SUP>TM</SUP> </P>
<P align="justify">
ViPova<SUP>TM</SUP> uses only legal CBD oil extracts, grown from legal hemp in locations where it is legal to do so, in ViPova<SUP>TM</SUP>-branded tea. ViPova<SUP>TM</SUP> uses its patent-pending process to infuse concentrated amounts of CBD within
lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova<SUP>TM</SUP> has this ground-breaking technology for CBD/lipid infusion. www.vipova.com </P>
<P align="justify">
FOR FURTHER INFORMATION PLEASE CONTACT:</P>
<P align="justify">
Lexaria Corp.<BR>
Chris Bunka<BR>
Chairman &amp; CEO<BR>
(250) 765-6424 <BR>
</P>
<P align="justify">
FORWARD-LOOKING STATEMENTS </P>
<P align="justify">
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations,
cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is
no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from
those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in
these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain
any beneficial human health conditions
whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or prevent any disease. </P>

<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
